MCM
RCKT icon

Monimus Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Monimus Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-153,728
Closed -$550K – 65
2026
Q1 		$550K Buy
153,728
+15,716
+11% +$62.5K 0.15% 55
2025
Q4 		$484K Buy
+138,012
New +$473K 0.32% 55

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Monimus Capital Management's RCKT Position: Q2 2026 in Review

Monimus Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 153,728 shares — an estimated $550K sold.

Monimus Capital Management first reported a position in RCKT in Q4 2025 and held it in 2 quarters. The position peaked at $550K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Monimus Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Monimus Capital Management sold 153,728 Rocket Pharmaceuticals shares in Q2 2026, an estimated $550K.
  • Monimus Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Monimus Capital Management's Rocket Pharmaceuticals position peaked at $550K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Monimus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.